Target intelligence / Profile preview

Epidermal tight junction (TJ) (TJ)

Target
TJ
Molecular classification
Cell-cell junction, Protein complex, Cell adhesion molecule
01

Overview

Epidermal tight junctions (TJs) are specialized cell-cell adhesion complexes located primarily in the stratum granulosum of the epidermis, where they form a critical paracellular barrier (Kubo et al., 2009, PMID: 19172026). These structures are composed of transmembrane proteins such as claudins (notably Claudin-1), occludin, and tricellulin, which are anchored to the cytoskeleton by scaffolding proteins like zonula occludens-1 (ZO-1) (Tokumasu et al., 2016, PMID: 27164494). The primary biological function of epidermal TJs is to regulate the movement of water, ions, and solutes, thereby preventing transepidermal water loss and protecting against environmental insults (StatPearls, 2023). In inflammatory conditions like atopic dermatitis, the expression of TJ proteins is significantly reduced, often driven by Th2 cytokines like IL-4 and IL-13, leading to barrier dysfunction (De Benedetto et al., 2011, PMID: 21085110). Therapeutic interventions such as JAK inhibitors (e.g., Upadacitinib) and biologics (e.g., Dupilumab) aim to restore the integrity of these junctions by suppressing inflammatory pathways that downregulate TJ components (Bissonnette et al., 2021, PMID: 33582250).

Other names
Skin barrier structuresZonula occludensStratum granulosum tight junctionsParacellular barrier
02

Mechanism of action

Restoration of the skin barrier through the upregulation of tight junction proteins (e.g., Claudin-1, ZO-1) by inhibiting pro-inflammatory cytokines or signaling pathways (e.g., JAK/STAT) that suppress their expression (De Benedetto et al., 2011, PMID: 21085110).

03

Biological functions

Barrier functionParacellular transport regulationCell polarityInnate immune defense
04

Disease associations

Atopic dermatitisPsoriasisIchthyosisSkin infectionNetherton syndrome
05

Safety considerations

Increased systemic exposure of topically applied drugs due to barrier impairmentPotential for off-target effects on tight junctions in other epithelial tissues like the gut or kidney
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Transepidermal water loss (TEWL)Claudin-1 expressionZonula occludens-1 (ZO-1) expressionFilaggrin levels

Beyond the preview

Go deeper on Epidermal tight junction (TJ) (TJ).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epidermal tight junction (TJ) (TJ).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call